BofA raised the firm’s price target on Progyny (PGNY) to $34 from $30 and keeps a Buy rating on the shares. Progyny’s Q4 results reflect improving utilization trends, which suggests softer utilization trends earlier in the year are not structural, the analyst tells investors. BofA remains optimistic on end market demand in the fertility space and Progyny’s “leading position,” the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY:
- Progyny’s Strong Financial Performance and Growth Prospects Drive Buy Rating
- Progyny’s Balanced Outlook: Strong Performance Amidst Transition Challenges and Conservative Projections
- Progyny, Inc. Reports Strong 2024 Financial Results
- Closing Bell Movers: HP slips 4% as guidance disappoints; Elastic up 15%
- Progyny sees Q1 adjusted EPS 44c-47c, consensus 40c